



Rec'd 1646#5
DMJ
3-14-02

TECH CENTER 1600/2900
MAR 14 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

M. Patricia Beckmann et al.

Serial No: 09/904,954

Docket No.: 2814-G

Group Art Unit: 1646

Filed: July 12, 2001

Examiner: unknown

For: CYTOKINES THAT BIND THE CELL SURFACE RECEPTOR HEK

INFORMATION DISCLOSURE STATEMENT

BOX NON-FEE

Assistant Commissioner of Patents
Washington, DC 20231

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449. The aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which may be material to the examination of the above-identified application. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

The present application is a divisional of application serial no. 09/358,734 filed July 21, 1999, which is a divisional of application serial no. 09/057,121 filed April 8, 1998, which is a divisional of application serial no. 08/453,943 filed May 30, 1995, which is a divisional of application serial no. 08/240,124 filed May 9, 1994, which is a continuation-in-part of 08/161,132 filed December 3, 1993, which is a continuation-in-part of 08/114,426 filed August 30, 1993, which is a continuation-in-part of 08/109,745 filed August 20, 1993.

Each reference listed on the enclosed Form PTO-1449 was cited by or submitted to the U.S. Patent and Trademark Office in one of the prior applications identified above. Pursuant to 37 C.F.R. § 1.98(d), copies of references already cited by the U.S. Patent and Trademark Office or submitted in a prior application (from which the present application claims priority under 35 U.S.C. § 120) are not required to be submitted with the present information disclosure statement.

Submission of these documents does not constitute an admission that they are "prior art" under 35 U.S.C. §102 or §103, and applicants specifically reserve the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method. Applicants submit that the claims of the above-captioned application are directed to subject matter that is patentably distinct from the disclosure of the cited references.

Since the submission of the documents listed on the Form PTO-1449 is made before the mailing of the first Office Action in connection with the above-captioned application, no fee under 37 C.F.R. 1.17(p) is believed to be required. However, should it be determined that a fee is necessary, applicants authorize the Commissioner to charge applicants' deposit account no. 09-0089 in an amount necessary to permit consideration of this Information Disclosure Statement.

Respectfully submitted,



Randolph N. Mohr, Ph.D.
Registration No. 45,590
DIRECT DIAL (206) 381-6071

Immunex Corporation
Law Department
51 University Street
Seattle, WA 98101
Telephone: (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service as first-class mail under 37 CFR §1.8 on the date indicated below, and is addressed to: BOX NON-FEE, Assistant Commissioner for Patents, Washington, DC 20231.

Date: February 27, 2002

By: 
D.F. Lindholm